Nurix Therapeutics (NRIX) Current Leases (2021 - 2026)

Nurix Therapeutics (NRIX) has 6 years of Current Leases data on file, last reported at $3.2 million in Q1 2026.

• Current Leases for Q1 2026 came in at $3.2 million, down 51.77% year-over-year; the trailing twelve-month figure through Feb 2026 was $3.2 million (down 51.77% YoY), and the FY2025 annual result was $2.8 million, down 64.76% from the prior year.
• Current Leases rose to $3.2 million in Q1 2026 per NRIX's latest filing, from $2.8 million in the prior quarter.
• Over five years, Current Leases peaked at $8.0 million in Q4 2024 and troughed at $2.8 million in Q4 2025.
• A 5-year average of $5.7 million and a median of $5.5 million in 2022 frame the typical range for Current Leases.
• The sharpest annual moves came in 2022 and 2025: Current Leases jumped 43.75% in 2022, then tumbled 64.76% in 2025.
• A 5-year view of Current Leases shows it stood at $5.5 million in 2022, then surged by 35.42% to $7.5 million in 2023, then advanced by 7.01% to $8.0 million in 2024, then plunged by 64.76% to $2.8 million in 2025, then grew by 13.39% to $3.2 million in 2026.
• Business Quant data shows NRIX's Current Leases at $3.2 million in Q1 2026, $2.8 million in Q4 2025, and $3.8 million in Q3 2025.